Assessing eligibility for treatment in acute myeloid leukemia in 2023.

Adriano Venditti, Roberto Cairoli, Morena Caira, Paola Finsinger, Fabio Finocchiaro, Benedetta Neri, Daniela De Benedittis, Giuseppe Rossi, Felicetto Ferrara

Expert review of hematology 2023 Mar

filter terms:

Age has historically been considered the main criterion to determine eligibility for intensive chemotherapy in patients with acute myeloid leukemia (AML), but age alone can no longer be considered an absolute indicator in determining which patients should be defined as unfit. Assessment of fitness for a given treatment today serves an important role in tailoring therapeutic options. This review examines the main options used in real life to define eligibility for intensive and nonintensive chemotherapy in patients with AML, with a main focus on the Italian SIE/SIES/GITMO Consensus Criteria. Other published real-life experiences are also reviewed, analyzing the correlation between these criteria and short-term mortality, and thus expected outcomes. Assessment of fitness is mandatory at diagnosis to tailor treatment to the greatest degree possible, evaluating the patient's individual profile. This is especially relevant when considering the availability of newer, less toxic therapeutic regimens, which have shown promising results in patients with AML who are older or considered unfit for intensive treatment. Fitness assessment is now a fundamental part of AML management and a critical step that can potentially influence outcomes and not just predict them.

Citation

Adriano Venditti, Roberto Cairoli, Morena Caira, Paola Finsinger, Fabio Finocchiaro, Benedetta Neri, Daniela De Benedittis, Giuseppe Rossi, Felicetto Ferrara. Assessing eligibility for treatment in acute myeloid leukemia in 2023. Expert review of hematology. 2023 Mar;16(3):181-190